Reuters logo
BRIEF-Novan announces first patient dosed in phase 1B Atopic Dermatitis trial With Sb414
December 5, 2017 / 2:05 PM / 8 days ago

BRIEF-Novan announces first patient dosed in phase 1B Atopic Dermatitis trial With Sb414

Dec 5 (Reuters) - Novan Inc:

* NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414

* NOVAN INC - ‍ TOP LINE RESULTS FROM PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414​ ARE TARGETED FOR Q3 OF 2018

* NOVAN INC - ‍TOP LINE RESULTS ARE TARGETED FOR Q2 OF 2018 FROM PREVIOUSLY ANNOUNCED PHASE 1B CLINICAL TRIAL WITH SB414 FOR TREATMENT OF PSORIASIS​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below